Report Details:
15 Companies Covered
203 Pages
Market Highlights
Yeast Infection Market Size was estimated at 4.88 USD Million in 2024. The Yeast Infection industry is projected to grow from 5.27 USD Million in 2025 to 10.08 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.77% during the forecast period 2025 - 2035.
The global yeast infection market is expecting a steady growth during the forecasted period. Candida albicans is most common yeast causing this infection. Growing geriatric population, increasing prevalence of autoimmune diseases, elevating number of patients suffering from HIV and advancement in the treatment have driven the market growth.
Moreover, increasing healthcare expenditure, and rising demand for the better treatment have fueled the growth of the market. However, side effects of the treatment and poor reimbursement policies in developed countries may slow the growth of this market.
Regional Analysis
Geographically, the global yeast infection market is segmented into four major regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas dominate the global yeast infection market owing to the presence of huge geriatric population and population suffering from autoimmune diseases. America is further segmented into North America and South America. North America holds the largest market owing to extensive use of advanced technology and developed pharmaceutical sector.
Europe accounts for the second largest market due to increasing funds, government support and increasing healthcare expenditure. Asia Pacific is the fastest growing market for the yeast infection, whose growth is attributed to rising geriatric population, increasing prevalence of people suffering from HIV and rapidly developing economies.
On the other hand, the Middle East & Africa is expected witness limited growth due to limited access to the healthcare resources and lack of awareness & advanced technology.
Segmentation
The global yeast infection market is segmented on the basis of pathogen, types, treatment, and end users. On the basis of pathogens, the market is segmented into Candida albicans, Candida glabrata, Candida rugosa, and others.
On the basis of types, the market is categorized into vaginal yeast infection, skin yeast infection, throat yeast infection, and others.
On the basis of treatment, the market is segmented into drug treatment and surgery. Drug treatment is further classified into cream, ointment, tablet, and suppository.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers and others.
Key Players
Some of the key players in yeast infection market are Scynexis (US), Synmedic Laboratories (India), Merck & Co., Inc. (US), Astellas (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Abbott (US), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), ALLERGAN (Ireland), AstraZeneca (UK).
The global yeast infection market is very competitive in nature. The companies are focusing on the new product developments. Whereas, some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.
Merck & Co., Inc. holds a healthy share of the global yeast infection market owing to the Cancidas, Noxafil and VETRANAL which are some of the top selling drugs worldwide.
